Distinct secreted frizzled receptor protein 1 staining pattern in patients with hyperplastic polyposis coli syndrome

Archives of Pathology and Laboratory Medicine

Volumn 128, Issue 9, 2004, Pages 967-973

  Oberschmid, Barbara I ^a   Dietmaier, Wolfgang ^a   Hartmann, Arndt ^a   Dahl, Edgar ^b   Klopocki, Eva ^c   Beatty, Barbara G ^d   Hyman, Neil H ^e   Blaszyk, Hagen ^d  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF VERMONT   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYRIBONUCLEOPROTEIN; FRIZZLED PROTEIN; FRIZZLED RECEPTOR PROTEIN 1; FRIZZLED RECEPTOR PROTEIN 3; MISMATCH REPAIR PROTEIN; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; PROTEIN P53; UNCLASSIFIED DRUG; WNT PROTEIN;

ARTICLE; CELL GROWTH; CHROMOSOME 8P; CLINICAL ARTICLE; COLON CARCINOGENESIS; COLON POLYPOSIS; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; HYPERPLASTIC POLYPOSIS COLI SYNDROME; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; METHYLATION; PRECANCER; PROTEIN SECRETION; RECEPTOR GENE; REPRODUCIBILITY; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; AGED; CARRIER PROTEINS; COLONIC POLYPS; COLORECTAL NEOPLASMS; DNA-BINDING PROTEINS; FEMALE; HUMANS; HYPERPLASIA; IMMUNOENZYME TECHNIQUES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTESTINAL POLYPOSIS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTS HOMOLOG 2 PROTEIN; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; WNT PROTEINS;

EID: 4444232874     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Rashid A, Houlihan PS, Booker S, Petersen GM, Giardiello FM, Hamilton SR. Phenotypic and molecular characteristics of hyperplastic polyposis. Gastroenterology. 2000;119:323-332.
2. Hawkins NJ, Corman P, Tomlinson NJ, Bullpit P, Ward RL. Colorectal carcinomas arising in the hyperplastic polyposis syndrome progress through the chromosomal instability pathway. Am J Pathol. 2000;157:385-392.
3. Burt R, Jass JR. Hyperplastic polyposis. In: Hamilton SR, Aaltonen LA, eds. Pathology and Genetics of Tumours of the Digestive System. Lyon, France: IARC Press; 2000:135. World Health Organization Classification of Tumours; vol 2.
4. Jass JR. Hyperplastic-like polyps as precursors of microsatellite unstable colorectal cancer. Am J Clin Pathol. 2003;119:773-775.
5. Goldstein NS, Bhanot P, Odish E, Hunter S. Hyperplastic-like colon polyps that preceded microsatellite unstable adenocarcinomas. Am J Clin Pathol. 2003; 119:778-796.
6. Torlakovic E, Skovlund E, Snover DC, Torlakovic C, Nesland JM. Morphologic reappraisal of serrated colorectal polyps. Am J Surg Pathol. 2003;27:65-81.
7. Torlacovic E, Snover DC. Serrated adenomatous polyposis in humans. Gastroenterology. 1996;10:748-755.
8. Muller A, Fishel R. Mismatch repair and the hereditary non-polyposis colorectal cancer syndrome (HNPCC). Cancer Invest. 2002;20:102-109.
9. Peltomaki P, Vasen HF. Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology. 1997;113:1146-1158.
10. Fishel R. The selection for mismatch repair defects in hereditary nonpolyposis colorectal cancer: revising the mutator hypothesis. Cancer Res. 2001;61: 7369-7374.
11. Loeb LA. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res. 1991;51:3075-3079.
12. Perucho M. Cancer of the microsatellite mutator phenotype. Biol Chem. 1996;377:675-684.
13. Bocker T, Ruschoff J, Fishel R. Molecular diagnostics of cancer predisposition: hereditary non-polyposis colorectal carcinoma and mismatch repair defects. Biochim Biophys Acta. 1999;1423:O1-O10.
14. Loeb LA. A mutator phenotype in cancer. Cancer Res. 2001;61:3230-3239.
15. Jass JR, Iino H, Ruszkiewicz A, et al. Neoplastic progression occurs through mutator pathways in hyperplastic polyposis of the colorectum. Gut. 2000;47:43-49.
16. Chan A, Issa J-PJ, Morris JS, Hamilton SR, Rashid A. Concordant CpG island methylation in hyperplastic polyposis. Am J Pathol. 2002;60:529-536.
17. Brabletz T, Jung A, Kirchner T. β-Catenin and the morphogenesis of colorectal cancer. Virchows Arch. 2002;441:1-11.
18. Üren A, Reichsman F, Anest V, et al. Secreted Frizzled-related protein-1 binds directly to Wingless and is a biphasic modulator of Wnt signaling. J Biol Chem. 2000;275:4374-4382.
19. Bafico A, Gazit A, Pramila T, Finch P, Yaniv A, Aaronson S. Interaction of frizzled related protein (FRP) with Wnt ligands and the frizzled receptor suggests alternative mechanisms for FRP inhibition of Wnt signaling. J Biol Chem. 1999; 274:16180-16187.
20. Yaremko M, Kutza C, Lyzak J, Mick R, Recant W, Westbrook C. Loss of heterozygosity from the short arm of chromosome 8 is associated with invasive behavior in breast cancer. Genes Chromosomes Cancer. 1996;16:189-195.
21. Suzuki H, Gabrielson E, Chen W, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet. 2002;31:141-9.
22. Hartmann A, Zanardo L, Bocker-Edmonston T, et al. Frequent microsatellite instability in sporadic tumors of the upper urinary tract. Cancer Res. 2002;62: 6796-6802.
23. Stoehr R, Wissmann C, Suzuki H, et al. Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab Invest. 2004;84:465-478.
24. Holmgren L, Glaser A, Pfeifer-Ohlsson S, Ohlsson R. Angiogenesis during human extraembryonic development involves the spatiotemporal control of PDGF ligand and receptor gene expression. Development. 1991;113:749-754.
25. Finch PW, He X. Purification and molecular cloning of a secreted, Frizzled-related antagonist of Wnt action. Proc Natl Acad Sci U S A. 1997;94:6770-6775.
26. Melkonyan H, Chang W, Shapiro J, et al. SARPs: a family of secreted apoptosis-related proteins. Proc Natl Acad Sci U S A. 1997;94:13636-13641.
27. Seiki M. Membrane-type matrix metalloproteinases. APMIS. 1999;107: 137-143.
28. Imanishi Y, Fujii M, Tokumaru Y, et al. Clinical significance of expression of membrane type 1 matrix metalloproteinase and matrix metalloproteinase-2 in human head and neck squamous cell carcinoma. Hum Pathol. 2000;31:895-904.
29. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene. 2002;21:5427-5440.
30. Suzuki H, Watkins DN, Jair KW, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet. 2004; 36:417-422.
31. Caldwell GM, Jones C, Gensberg K, et al. The Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Res. 2004;64:883-888.